Business
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full
About this update from Eikon Therapeutics, Inc.
[{"type":"image","alt":"Eikon Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Eikon Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":194,"url":"https://media.zenfs.com/en/globenewswire.com/4244084826f1ce90c788c046545dcf21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CHhUx_SPC_mefYX2YC_FDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Mg--/https://media.zenfs.com/en/globenewswire.com/4244084826f1ce90c788c046545dcf21","width":300,"height":194}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer ","length":127,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":222,"olType":false},{"type":"text","content":"MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates.","length":336,"tagName":"p"},{"type":"text","content":"“2025 was an important year of progress for Eikon’s business and clinical programs,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. “With our initial public offering, and the consequent strengthening of our balance sheet, we believe we are well-positioned to advance multiple registration-enabling programs, bringing us closer to our mission of delivering breakthrough therapeutics to patients with serious illnesses.”","length":460,"tagName":"p"},{"type":"text","content":"Pipeline Updates","length":16,"tagName":"p"},{"type":"text","content":"The following paragraphs describe progress made in advancing Eikon’s clinical programs through the end of 2025.","length":111,"tagName":"p"},{"type":"text","content":"EIK1001 is a systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses. Phase 1 studies have previously shown that EIK1001 exhibits single-agent activity in patients with ad...